Vanguard Group Inc. boosted its holdings in Pacific Biosciences of California, Inc. (NASDAQ:PACB) by 7.8% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,929,300 shares of the biotechnology company’s stock after buying an additional 283,216 shares during the quarter. Vanguard Group Inc. owned approximately 4.04% of Pacific Biosciences of California worth $13,988,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in PACB. Frontier Capital Management Co. LLC acquired a new stake in Pacific Biosciences of California during the 2nd quarter valued at approximately $5,363,000. Morgan Stanley increased its position in Pacific Biosciences of California by 129.0% during the 1st quarter. Morgan Stanley now owns 773,519 shares of the biotechnology company’s stock valued at $3,998,000 after purchasing an additional 435,774 shares during the period. Kennedy Capital Management Inc. increased its position in Pacific Biosciences of California by 52.4% during the 2nd quarter. Kennedy Capital Management Inc. now owns 1,240,391 shares of the biotechnology company’s stock valued at $4,416,000 after purchasing an additional 426,269 shares during the period. Spark Investment Management LLC acquired a new stake in Pacific Biosciences of California during the 2nd quarter valued at approximately $1,352,000. Finally, Trellus Management Company LLC increased its position in Pacific Biosciences of California by 67.1% during the 2nd quarter. Trellus Management Company LLC now owns 525,000 shares of the biotechnology company’s stock valued at $1,869,000 after purchasing an additional 210,800 shares during the period. 65.22% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: This article was originally published by Daily Political and is the sole property of of Daily Political. If you are accessing this article on another site, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The original version of this article can be viewed at https://www.dailypolitical.com/2017/11/20/vanguard-group-inc-raises-position-in-pacific-biosciences-of-california-inc-pacb.html.

A number of analysts have weighed in on the stock. Zacks Investment Research downgraded shares of Pacific Biosciences of California from a “buy” rating to a “hold” rating in a research report on Thursday, August 10th. BidaskClub raised shares of Pacific Biosciences of California from a “strong sell” rating to a “sell” rating in a research report on Tuesday, August 8th. CL King downgraded shares of Pacific Biosciences of California from a “buy” rating to a “neutral” rating and set a $6.80 target price for the company. in a research report on Thursday, September 28th. Finally, First Analysis downgraded shares of Pacific Biosciences of California from an “overweight” rating to an “equal weight” rating and set a $4.00 target price for the company. in a research report on Friday, November 3rd. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and one has given a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $6.27.

Shares of Pacific Biosciences of California, Inc. (NASDAQ:PACB) opened at $2.98 on Monday. The company has a debt-to-equity ratio of 0.10, a current ratio of 3.75 and a quick ratio of 3.15. Pacific Biosciences of California, Inc. has a 52-week low of $2.66 and a 52-week high of $8.00.

Pacific Biosciences of California (NASDAQ:PACB) last announced its quarterly earnings data on Thursday, November 2nd. The biotechnology company reported ($0.19) EPS for the quarter, topping the consensus estimate of ($0.20) by $0.01. The company had revenue of $23.54 million during the quarter, compared to the consensus estimate of $28.29 million. Pacific Biosciences of California had a negative net margin of 95.97% and a negative return on equity of 97.50%. The company’s quarterly revenue was down 6.3% on a year-over-year basis. During the same quarter last year, the firm posted ($0.19) EPS. equities research analysts expect that Pacific Biosciences of California, Inc. will post -0.88 earnings per share for the current fiscal year.

About Pacific Biosciences of California

Pacific Biosciences of California, Inc designs, develops and manufactures sequencing systems to help scientists resolve genetically complex problems. The Company is engaged in the development, manufacturing and marketing of an integrated platform for genetic analysis. Its Single Molecule, Real-Time (SMRT) technology enables single molecule, real-time detection of biological processes.

Institutional Ownership by Quarter for Pacific Biosciences of California (NASDAQ:PACB)

Receive News & Ratings for Pacific Biosciences of California Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacific Biosciences of California Inc. and related companies with MarketBeat.com's FREE daily email newsletter.